Pharmaceutical giants are aggressively expanding internal manufacturing capabilities to resolve persistent global shortages of GLP-1 receptor agonists. Bottlenecks in sterile filling and auto-injector assembly have hindered revenue growth despite surging market demand for obesity and diabetes therapies.
Supply Chain Vertical Integration
To mitigate contract manufacturer capacity shortfalls, industry leaders are shifting toward direct acquisitions of fill-finish plants. Industry filings show capital commitments exceeding $15 billion toward dedicated manufacturing facilities over the next three fiscal years, reflecting a fundamental pivot toward vertical integration within metabolic disease portfolios.